Health Care | Federal Trade Commission

Skip to main content

Refine your results

Filters

Content type

Mission

Displaying 1141 - 1160 of 1576

Cases and Proceedings

Allergan, Inc., and Inamed Corporation, In the Matter of

The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.

Type of Action

Administrative

Last Updated

April 21, 2006

FTC Matter/File Number

061 0031

Docket Number

C-4156

Commission Approves Final Consent Order in Matter of Allergan/Inamed

Date

April 21, 2006

Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning Allergan, Inc.’s acquisition...

Report

Agreements Filed With the Federal Trade Commission Under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Summary of Agreements Filed in Fiscal Year 2005: A Report by the Bureau of Competition

Date

April 1, 2006

Text of the Commission Report (133.84 KB)

Maintaining Competition, FTC Allows Fresenius $3.5 Billion Deal to Buy Rival Dialysis Provider Renal Care Group

Date

March 31, 2006

Fresenius AG will sell 91 outpatient kidney dialysis clinics and financial interests in 12 more to settle Federal Trade Commission charges that Fresenius’ purchase of rival dialysis provider Renal...

FTC Proposes Study of Competitive Impacts of Authorized Generic Drugs

Date

March 29, 2006

The Federal Trade Commission today announced its intention to conduct a study of the use, and likely short- and long-term competitive effects, of authorized generics in the prescription drug...

Hospitals Plan for Collective Bargaining of Physicians Fees Likely Would Violate Federal Laws, FTC Staff Says

Date

March 28, 2006

A proposed plan by a physician-hospital organization that would involve collective bargaining with insurers over doctor fees likely would violate federal antitrust laws, according to the FTC staff...

Cases and Proceedings

Health Care Alliance of Laredo, L.C., In the Matter of

A physicians’ independent practice association in Texas agreed to settle charges that it engaged in unlawful collective bargaining to set fees its members would accept from health insurance plans and advised its members against dealing individually with plans. The Commission charged that both practices resulted in higher medical costs for consumers. The consent order settling the FTC’s charges will prohibit the IPA from engaging in such anticompetitive conduct in the future.

Type of Action

Administrative

Last Updated

March 28, 2006

FTC Matter/File Number

0410097

Preserving Competition, FTC Requires Divestiture Before Allowing Allergans Acquisition of Inamed

Date

March 8, 2006

Botox marketer Allergan, Inc., and the Inamed Corporation will divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle Federal Trade Commission charges that Allergan’s...

Cases and Proceedings

Teva Pharmaceutical Industries Ltd. and IVAX Corporation, In the Matter of

The consent order allowed Teva to acquire IVAX Corporation, provided the companies sell the rights and assets needed to manufacture and market 15 generic pharmaceutical products. Among the drugs sold were several forms of generic amoxicillin and amoxicillin clavulanate potassium that are widely used in the United States.

Type of Action

Administrative

Last Updated

March 7, 2006

FTC Matter/File Number

051 0214

Docket Number

C-4155

FTC Staff Files Comments on New Jerseys Proposed Advertising Guideline 4; Commission Finalizes Teva/Ivax Consent Order

Date

March 7, 2006

Commission authorization of the filing of staff comment:The Commission has authorized the staffs of the Bureau of Consumer Protection, Bureau of Economics, and Office of Policy Planning to file a...

Texas Doctors' IPA Agrees to Settle Price Fixing Charges

Date

February 13, 2006

A physicians’ independent practice association (IPA) in Texas has agreed to settle Federal Trade Commission charges that it engaged in unlawful collective bargaining to set fees its members would...

Davita Inc. Submits Petition for Approval of Proposed Divestiture; FTC Submits Budget Request and Performance Plans to Congress

Date

February 7, 2006

Petition for proposed divestiture: The Commission has received a petition from DaVita Inc. (DaVita) requesting approval of a proposed divestiture related to its recent acquisition of Gambro Healthcare...

Announced Action for January 27, 2006

Date

January 27, 2006

Commission authorization of the filing of staff comment: The Commission has authorized the staffs of the Office of Policy Planning, Bureau of Consumer Protection, and Bureau of Economics to file a...

Preserving Competition, FTC Requires Divestitures Before Allowing Tevas $7.4 Billion Acquisition of IVAX

Date

January 23, 2006

Under a consent agreement announced today, the Federal Trade Commission will allow Teva Pharmaceutical Industries Ltd.’s (Teva) proposed acquisition of IVAX Corporation (IVAX), provided the companies...

Commission Finds That North Texas Specialty Physicians Illegally Fixed Prices

Date

December 1, 2005

In a unanimous administrative opinion and order made public today, the Federal Trade Commission ruled that North Texas Specialty Physicians (NTSP), an association of independent physicians in the...

In re Tamoxifen Citrate Antitrust Litigation

Date

November 30, 2005

Citation Number

03-7641

Federal Court

U.S. Circuit Court of Appeals for the Second Circuit

An amicus brief in support of plaintiffs-appellants’ petition for panel rehearing and rehearing en banc. The case concerns a decision by a divided panel of the appeals court upholding the dismissal...

In re Tamoxifen Citrate Antitrust Litigation (133.21 KB)

Announced Action for November 18, 2005

Date

November 18, 2005

Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning DaVita, Inc. and Gambro AB...

FTC Sues to Stop Anticompetitive Agreement in U.S. Drug Industry

Date

November 7, 2005

The Federal Trade Commission today filed a complaint in federal district court seeking to put an end to an agreement between drug manufacturers Galen Chemicals Ltd. (now known as Warner Chilcott) and...

Administrative Law Judge Orders Evanston Northwestern Healthcare Corporation to Sell Highland Park Hospital

Date

October 21, 2005

Evanston Northwestern Healthcare Corporation (ENH), located in Evanston, Illinois, must sell Highland Park Hospital (Highland Park) within 180 days, under the terms of an initial decision and order...

FTC Accepts Settlement to Remedy DaVita's Acquisition of Rival Outpatient Dialysis Clinic Provider Gambro

Date

October 4, 2005

The Federal Trade Commission today accepted for public comment an order resolving the competitive issues raised by DaVita, Inc.’s (DaVita) proposed $3.1 billion purchase of rival outpatient dialysis...

Displaying 1141 - 1160 of 1576